# US 11,078,235 B2 · Cyclic peptide conjugates and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,078,235 B2
- Document ID: US11078235B2
- Status: Granted
- Kind: B2
- Application number: 16/025,382
- Filed: 2018-07-02
- Published: 2019-03-28
- Granted: 2021-08-03
- Earliest claimed: 2013-09-27
- Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc.; The Scripps Research Institute; University of South Florida
- Applicants: H. Lee Moffitt Cancer Center And Research Institute, Inc.; University of South Florida; The Scripps Research Institute; Modulation Therapeutics
- Inventors: Lori Hazlehurst; Christoph Rader; Xiuling Li; Mark McLaughlin
- Web page: https://patentgrep.com/patent/US11078235B2

## CPC

- C07K 7/06: having 5 to 11 amino acids
- C07K 1/00: General methods for the preparation of peptides {, i.e. processes for the organic chemical preparation of peptides or proteins of any length}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/21: containing a His-tag
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).

## Claims

### Claim 1

A carrying agent:cyclic compound adduct having the structure:
wherein X comprises a carrying agent and z is 1 to 20.

### Claim 2 (depends on 1)

The carrying agent:cyclic compound adduct of claim 1, wherein said carrying agent comprises an amino acid, oligo(amino acid), poly(amino acid) or protein.

### Claim 3 (depends on 2)

A composition comprising a cyclic compound of claim 2; and a pharmaceutically acceptable carrier.